#123 A Serendipitous Discovery and Novel Treatment for Infantile Hemangiomas
CLINICAL QUESTION
Are beta-blockers effective in treating small infantile hemangiomas?
BOTTOM LINE
One small randomized controlled trial (RCT) and numerous observational studies demonstrate that oral propranolol stops growth and induces regression of infantile hemangiomas (IH) by four weeks. Similar evidence suggests topical timolol stops IH growth and induces regression by >5% after 4-6 months for every one in 2-3 patients.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Oral Propranolol:
- RCT (40 children, aged nine weeks to five years, followed x 6.0 months).1 Compared to placebo, propranolol 2mg/kg (divided three times per day) statistically significantly:
- Stopped IH growth by week four for all children.
- Reduced IH volume at all weeks (example Week 12: -48.5% vs. +17.9%).
- No significant hypotension, hypoglycemia, or bradycardia.
- Systematic review (40 observational studies plus above RCT,1 1,264 children, mean age 6.6 months, treated x 6.4 months):2
- Mean response rate (any improvement) 98%.
- Serious side effects rare: symptomatic hypotension, bradycardia, or hypoglycemia in ten.
- RCT (41 children, median nine weeks old).3 At 20-24 weeks, significantly more IHs with one drop timolol maleate 0.5% gel twice a day vs. placebo:
- Decreased in size by >5% (vs. normal increase in size at this age) Number Needed to Treat (NNT)=3.
- Limitations: Small numbers.
- Prospective clinical study (124 children, ≤12 months age).4 At four months, significantly more in timolol group than observational group reported:
- IH stopped growing and/or became smaller, 92% vs. 34%, NNT=2.
- No serious adverse events.
- Numerous smaller retrospective cohort and prospective clinical studies report similar findings.5-9
- Beta-blockers for IH first reported in 2008 when two infants started on propranolol for cardiac reasons experienced dramatic involution of severe hemangiomas.10
- Hemangiomas often develop in the first few weeks of life, reach 80% of their final size by three months and 80% complete growth by five months.11 By five years the majority of lesions completely disappear without treatment.12
- Oral propranolol FDA-approved for severe IHs.13 No beta-blocker approved by Health Canada for this.
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
